Cargando…

Effectiveness of empiric aztreonam compared to other beta-lactams for treatment of Pseudomonas aeruginosa infections

PURPOSE: To evaluate the use of aztreonam as an active empiric therapy against subsequent culture of Pseudomonas aeruginosa (P. aeruginosa). METHODS: This was a retrospective cohort study conducted among patients who received either aztreonam or an antipseudomonal beta-lactam (BL) as an empiric ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hogan, Michael, Bridgeman, Mary Barna, Min, Gee Hee, Dixit, Deepali, Bridgeman, Patrick J, Narayanan, Navaneeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208932/ https://www.ncbi.nlm.nih.gov/pubmed/30464539 http://dx.doi.org/10.2147/IDR.S174570

Ejemplares similares

1601. Evaluation of Synergy with β-Lactams Plus Aztreonam Against Pseudomonas aeruginosa (PSA)
por: O’Donnell, J Nicholas, et al.
Publicado: (2019)

Constipation in Elderly Patients with Noncancer Pain: Focus on Opioid-Induced Constipation
por: Chokhavatia, Sita, et al.
Publicado: (2016)

Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence in Pseudomonas aeruginosa
por: Jorth, Peter, et al.
Publicado: (2017)

Overcoming barriers to intranasal corticosteroid use in patients with uncontrolled allergic rhinitis
por: Bridgeman, Mary Barna
Publicado: (2017)

Nonirritating skin test concentrations for ceftazidime and aztreonam in patients with a documented beta-lactam allergy
por: van der Poorten, Marie-Line M., et al.
Publicado: (2021)

Zonisamide-induced acute kidney injury
por: Dixit, Deepali, et al.
Publicado: (2015)

A MexR Mutation Which Confers Aztreonam Resistance to Pseudomonas aeruginosa
por: Ma, Zhenzhen, et al.
Publicado: (2021)

181 Empiric Coverage of ICU Patients for Infections Due to Beta-lactam Resistant Pseudomonas aeruginosa with Combination Therapy: A Needs Assessment
por: Cawcutt, Kelly, et al.
Publicado: (2014)

In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-β-lactamase-producing Pseudomonas aeruginosa
por: Oie, Shigeharu, et al.
Publicado: (2009)

In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia
por: Spottiswoode, Natasha, et al.
Publicado: (2023)

Pharmacists’ Perceptions and Drivers of Immunization Practices for COVID-19 Vaccines: Results of a Nationwide Survey Prior to COVID-19 Vaccine Emergency Use Authorization
por: Jacob, Sonia Susan, et al.
Publicado: (2021)

1600. Susceptibility of β-Lactam-Resistant Pseudomonas aeruginosa to Other β-Lactams: Is There Truly a Lack of Cross-Resistance?
por: Patel, Twisha S, et al.
Publicado: (2019)

239. Outcomes Associated with Empiric Aztreonam Use Compared to Anti-Pseudomonal β-lactams in Patients with Sepsis: An Opportunity for Allergy Stewardship
por: Jaffa, Rupal K, et al.
Publicado: (2020)

Evaluation of alterations in serum immunoglobulin concentrations in components of metabolic syndrome, obesity, diabetes, and dyslipidemia
por: Lin, Dee, et al.
Publicado: (2019)

Impact of Definitive Therapy with Beta-Lactam Monotherapy or Combination with an Aminoglycoside or a Quinolone for Pseudomonas aeruginosa Bacteremia
por: Bliziotis, Ioannis A., et al.
Publicado: (2011)

Beta-Lactam vs. Fluoroquinolone Monotherapy for Pseudomonas aeruginosa Infection: A Systematic Review and Meta-Analysis
por: Reid, Eric, et al.
Publicado: (2021)

In Vivo Development of Aztreonam Resistance in Meropenem-Resistant Pseudomonas aeruginosa Owing to Overexpression of the bla(PDC-16)
por: Ding, Li, et al.
Publicado: (2023)

2536. Comparing the activity of broad-spectrum beta-lactams in combination with aminoglycosides and aztreonam/avibactam against 8 VIM-producing CRE
por: Clark, Justin A, et al.
Publicado: (2023)

129. Beta-lactam vs Fluoroquinolone Monotherapy for pseudomonas Aeruginosa infection: A Systematic Review and Meta-analysis
por: Reid, Eric C, et al.
Publicado: (2020)

Aztreonam Lysine Increases the Activity of Phages E79 and phiKZ against Pseudomonas aeruginosa PA01
por: Davis, Carly M., et al.
Publicado: (2021)

In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa
por: Lomovskaya, Olga, et al.
Publicado: (2021)

Characterization of predictors of ESBL‐producing enterobacteriaceae in urine cultures of emergency department patients
por: Saadi, Raghad, et al.
Publicado: (2021)

β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects
por: Glen, Karl A., et al.
Publicado: (2021)

Pseudomonas aeruginosa Susceptibility Patterns and Associated Clinical Outcomes in People with Cystic Fibrosis following Approval of Aztreonam Lysine for Inhalation
por: Keating, Claire L., et al.
Publicado: (2021)

1114. Effectiveness and Safety of Beta-lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2021)

High prevalence of bla(VEB), bla(GES) and bla(PER) genes in beta-lactam resistant clinical isolates of Pseudomonas aeruginosa
por: Haghighi, Saboura, et al.
Publicado: (2022)

1686. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients
por: Sader, Helio S, et al.
Publicado: (2022)

Trimeric Tobramycin/Nebramine Synergizes β-Lactam Antibiotics against Pseudomonas aeruginosa
por: Dhiman, Shiv, et al.
Publicado: (2023)

1791. The Impact of a β-lactam Allergy Assessment on Aztreonam Utilization Within a Healthcare System
por: Shea, Katherine, et al.
Publicado: (2018)

Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus
por: Yim, Juwon, et al.
Publicado: (2016)

Co-regulation of β-lactam resistance, alginate production and quorum sensing in Pseudomonas aeruginosa
por: Balasubramanian, Deepak, et al.
Publicado: (2011)

Mortality in patients with carbapenem-resistant Pseudomonas aeruginosa with and without susceptibility to traditional antipseudomonal β-lactams
por: Howard-Anderson, Jessica, et al.
Publicado: (2021)

Beta lactam hypersensitivities
por: Azoury, Marie Eliane*, et al.
Publicado: (2014)

A Framework for Engaging Healthcare Professional Trainees as Continuing Education Activity Planners and Speakers
por: Bridgeman, Mary Barna, et al.
Publicado: (2023)

In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria
por: Emeraud, Cécile, et al.
Publicado: (2023)

Relation between Resistance to Antipseudomonal β-Lactams and ampC and mexC Genes of Pseudomonas aeruginosa
por: Rezaei, Fatemeh, et al.
Publicado: (2016)

Design and Synthesis of Lactams Derived from Mucochloric and Mucobromic Acids as Pseudomonas aeruginosa Quorum Sensing Inhibitors
por: Almohaywi, Basmah, et al.
Publicado: (2018)

Regulation of AmpC-Driven β-Lactam Resistance in Pseudomonas aeruginosa: Different Pathways, Different Signaling
por: Torrens, Gabriel, et al.
Publicado: (2019)

2269. Clinical Outcomes in Patients with Carbapenem-Non-Susceptible, β-Lactam-Susceptible Pseudomonas aeruginosa Infections
por: Gavaghan, Victoria M, et al.
Publicado: (2019)

Outcomes of adult patients in the intensive care unit with Pseudomonas aeruginosa pneumonia who received an active anti‐pseudomonal β‐lactam: Does “S” equal success in the presence of resistance to other anti‐pseudomonal β‐lactams?
por: Lodise, Thomas P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cl0uufci3pk2o0sgi2c7o8dt92